Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from InhaleRx Limited ( (AU:IRX) ).
InhaleRx Limited has issued 17,100,000 ordinary shares without disclosure to investors, in compliance with the Corporations Act. This move is part of their strategy to accelerate the development of their inhaled therapies, which could significantly impact the market by addressing critical gaps in treatment options for conditions like cancer pain and mental health disorders.
More about InhaleRx Limited
InhaleRx Limited is an Australian clinical stage drug development company focused on creating rapid onset, inhaled therapies for unmet medical needs in pain management and mental health. The company is working on treatments for Breakthrough Cancer Pain, Panic Disorder, and Treatment-Resistant Depression, aiming for U.S. FDA approval through efficient regulatory pathways.
Average Trading Volume: 253,643
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$5.7M
For an in-depth examination of IRX stock, go to TipRanks’ Overview page.